Faron reports 85% response rate in frontline higher-risk MDS trial of bexmarilimab combination

PUBT · 21h ago
Faron reports 85% response rate in frontline higher-risk MDS trial of bexmarilimab combination
  • Faron Pharmaceuticals will present five abstracts on bexmarilimab, Clever-1 biology and higher-risk MDS at ASH in New Orleans, December 12-15, 2026.
  • BEXMAB survival outcomes varied by TP53 mutation status, with the longest survival observed in previously treated patients without TP53 mutations.
  • Previously reported frontline results showed remissions with bexmarilimab combined with azacitidine; its safety profile appeared comparable to azacitidine alone.
  • The randomized Phase 2b BEXERA trial targets approximately 90 previously untreated patients to select a bexmarilimab dose for Phase 3 development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.